A Phase II Trial of Celecoxib Plus Interferon Alpha in Metastatic Renal Cell Carcinoma Patients With 3+ COX-2 Tumor Immunostaining.

Trial Profile

A Phase II Trial of Celecoxib Plus Interferon Alpha in Metastatic Renal Cell Carcinoma Patients With 3+ COX-2 Tumor Immunostaining.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Aug 2012

At a glance

  • Drugs Celecoxib (Primary) ; Interferon alpha-2b (Primary)
  • Indications Renal cell carcinoma
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 25 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Apr 2011 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
    • 12 Jan 2011 Planned End Date changed from 1 Dec 2010 to 1 Dec 2011as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top